Intranasal Vaccination
Intranasal Vaccination - Related Videos
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
0 Views •
Cited by 1 •
2015
There is an overall lack of knowledge about how vaccines work. Here we propose the combined use of reverse genetics and bone marrow chimeric mice to gain insight into the early host immune responses to vaccines with a special focus on dendritic cells and T cell immunity.
02:16
Intranasal Immunization with BCG in a Mouse Model
0 Views •
2025
This video demonstrates intranasal BCG immunization in mice, activating both innate and adaptive immune responses, leading to the development of lung-resident memory T cells and effector B cells, thus enhancing protection against Mycobacterium infections.
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
0 Views •
Cited by 14 •
2016
We herein detail the methodology followed to compare protective efficacy and lung immune response induced by intranasal and subcutaneous immunization with BCG in mouse model. Our results show the benefits of pulmonary vaccination and suggest a role for IL17-mediated response in vaccine-induced protection.
01:51
Vaccinations
0 Views •
2019
Overview Vaccination is the administration of antigenic material from pathogens to confer immunity against a specific microorganism. Vaccination primes the immune system to recognize and mount an immune response faster and more effectively if the real pathogen is encountered. Vaccinations are one of the most efficient ways to protect both individual humans and the general public from disease. A growing anti-vaccination skepticism risks the successes of vaccination programs that helped reduce...
07:15
Intranasal Administration of CNS Therapeutics to Awake Mice
0 Views •
Cited by 182 •
2013
A method to intranasally administer drugs to awake mice for the purpose of targeting the brain is described. This method allows for repeat dosing over long periods using intranasal administration of drug without anesthesia, and nose-to-brain delivery with minimal systemic exposure.
FAQs
Intranasal vaccination can engage immune cells in the nasal mucosa and associated lymphoid tissues, rather than relying only on responses generated elsewhere. This local stimulation supports secretory IgA, while also promoting systemic antibodies and T-cell responses. The combination matters because it links defense at a common pathogen entry site with broader immunological protection.
Formulation, dose, and delivery method are central variables because they can alter how effectively vaccine antigens stimulate mucosal and systemic immunity. Intranasal vaccination studies therefore compare these parameters while examining protection, durability, and safety. Such comparisons help determine whether a candidate produces a useful balance between local nasal defense and responses detectable throughout the body.
Compared with administration routes that do not directly target the nasal passages, this approach is designed to generate immunity where respiratory pathogens may first encounter the host. Its potential value is not limited to preventing disease after infection; local responses may also help limit pathogen entry, replication, and transmission in the upper respiratory tract.
At a basic research level, the workflow centers on introducing vaccine antigens through the nasal passages, then evaluating the resulting immune responses. Investigators can assess local secretory IgA together with systemic antibodies and T-cell responses, while varying dose or formulation. They also examine protection, durability, and safety to judge how delivery conditions affect performance.
Researchers apply intranasal vaccination primarily in the development of mucosal vaccines for respiratory viruses and bacteria. The route is especially relevant when studies aim to strengthen defenses in the upper respiratory tract, not merely measure systemic immunity. Findings can guide candidate development by showing whether a formulation produces local responses alongside broader immune activity.
In immunology and infection research, evaluation extends beyond whether an immune response appears. Studies consider how strongly and how durably protection develops, whether responses include secretory IgA, antibodies, and T cells, and whether administration remains safe. This integrated assessment connects mucosal biology with infection-control goals, including reduced pathogen replication or transmission.